Skip to main content

Table 1 Baseline characteristics of all studied patients

From: The effect of hepatitis C virologic clearance on cardiovascular disease biomarker lipoprotein-associated phospholipase A2 and its relation to serum lipids

Descriptive data
Age (years), mean ± SD (range) 46.878 ± 10.605 (30–68)
BMI (kg/m2), mean ± SD (range) 26.232 ± 2.140 (21–31)
Gender, n (%) Male 55 (61.11%)
Female 35 (38.89%)
Smoking, n (%) Smoker 18 (20%)
Non-smoker 72 (80%)
Hypertension, n (%) Hypertensive 15 (16.67%)
Normotensive 75 (83.33%)
Diabetes mellitus, n (%) Diabetic 7 (7.78%)
Pre-diabetic 13 (14.44%)
Non-diabetic 70 (77.78%)
FBG (mg/dl), mean ± SD (range) 89.989 ± 15.786 (66–135)
HbA1c (%), mean ± SD (range) 5.420 ± 0.609 (4.1–7)
Child score, n (%) A5 9 (40.91%)
9 (45%)
A6 12 (54.55%)
10 (50%)
B7 1 (4.55%)
1 (5%)
Fibrosis stage, n (%) F0 16 (17.78%)
F1 39 (43.33%)
F2 10 (11.11%)
F3 3 (3.33%)
F4 22 (24.44%)
DAA regimen, n (%) SOF/DCV 45 (50%)
SOF/DCV/RBV 45 (50%)
HCV RNA (IU/ml), median (IQR) 2,253,000 (573,662.25–4,000,000)
  1. Abbreviations: SD, standard deviation; n, number; BMI, body mass index; DAA, direct-acting antiviral; SOF, sofosbuvir; DCV, daclatasvir; RBV, ribavirin; FBG, fasting blood glucose; HCV, hepatitis C virus; RNA, ribonucleic acid; IQR, interquartile range